Back to Search Start Over

Strategies to Reduce Out-of-Pocket Medication Costs for Canadians Living with Heart Failure

Authors :
Catherine Demers
Graham R. McClure
William F. McIntyre
Peter Belesiotis
Gursharan Sohi
Abigail Hayes
Richard P. Whitlock
Gurneet Chahill
Wendy Bordman
Emilie P. Belley-Côté
Source :
Cardiovascular Drugs and Therapy. 35:1009-1023
Publication Year :
2020
Publisher :
Springer Science and Business Media LLC, 2020.

Abstract

Daily medication is the cornerstone of evidence-based therapy to reduce mortality and morbidity in patients with heart failure (HF). Up to 20% of Canadian patients pay for medications out of pocket. We sought to identify strategies that patients and prescribers can employ to reduce these costs. We collected data from outpatient pharmacies in Hamilton, Ontario. We determined prices for different medications in each of the drug classes recommended for HF with reduced ejection fraction in the Canadian Cardiovascular Society’s guidelines. We examined differences in dispensing and delivery fees and inquired about other cost-saving strategies. We collected data from 24 different pharmacies, including a selection of hospital-based, independent, and larger chain pharmacies. In the most extreme scenario (i.e., 90-day prescription instead of a 30-day prescription and the least expensive generic drug instead of the most expensive brand name drug), total medication costs can differ by up to $495.56 per month. Costs were affected by choice of agent within a drug class, generic versus brand-name drug, quantity dispensed, dispensing fee, and delivery cost. Prescription content, dispensing practice, and pharmacy choice can remarkably impact out-of-pocket costs for HF medications. Prescribers can reduce costs by writing 90-day prescriptions and choosing the lowest-cost generic drugs in each therapeutic class. Patients should consider the services received for their pharmacy dispensing fees, use free delivery services where needed, and request inexpensive generic drugs. Pharmacists can facilitate cost minimization without compromising therapeutic efficacy.

Details

ISSN :
15737241 and 09203206
Volume :
35
Database :
OpenAIRE
Journal :
Cardiovascular Drugs and Therapy
Accession number :
edsair.doi...........d926d84ccbe88476be84571b8ef4307e